|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q100490134
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010751.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q100490134
|
|
024
|
|
|
‡a
0000-0001-5862-3815
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q100490134
|
|
100
|
0 |
|
‡a
Sudhir B Malla
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Sudhir B Malla
‡c
onderzoeker
‡9
nl
|
|
670
|
|
|
‡a
Author's In-depth clinical and biological exploration of DNA Damage Immune Response (DDIR) as a biomarker for oxaliplatin use in colorectal cancer
|
|
670
|
|
|
‡a
Author's The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
|
|
909
|
|
|
‡a
(orcid) 0000000158623815
‡9
1
|
|
919
|
|
|
‡a
indepthclinicalandbiologicalexplorationofdnadamageimmuneresponseddirasabiomarkerforoxaliplatinuseincolorectalcancer
‡A
In-depth clinical and biological exploration of DNA Damage Immune Response (DDIR) as a biomarker for oxaliplatin use in colorectal cancer
‡9
1
|
|
919
|
|
|
‡a
aminoacidtransporterslc7a5isrequiredforefficientgrowthofkrasmutantcolorectalcancer
‡A
The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer
‡9
1
|
|
996
|
|
|
‡2
RERO|A003554455
|
|
996
|
|
|
‡2
DNB|1236179382
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
